LL-37 Dosage Guide: Research Protocols & Study Parameters
A clinical reference compiling published LL-37 dosage ranges from in vitro and preclinical research literature. This guide consolidates documented antimicrobial peptide protocols, cathelicidin concentration parameters, and study design conventions for researchers building reproducible experimental frameworks.
Understanding LL-37: The Human Cathelicidin Antimicrobial Peptide
LL-37 is the only human cathelicidin antimicrobial peptide, a 37–amino-acid cationic peptide cleaved from the C-terminal end of the precursor protein hCAP18. It functions as a central component of the innate immune system, contributing to host defense, antimicrobial activity, immune modulation, and tissue repair processes. Any review of LL-37 dosage in published literature begins with this dual functional identity — both a broad-spectrum antimicrobial agent and an immunomodulatory signaling peptide — because the relevant concentration range often depends on which activity a study aims to characterize. A 2020 review published in Frontiers in Immunology outlines this functional duality across multiple model systems.
Across the published research, LL-37 has been characterized as a cationic antimicrobial peptide with activity against gram-positive and gram-negative bacteria, certain enveloped viruses, and fungal pathogens. Beyond direct antimicrobial properties, in vitro studies have documented LL-37’s role in modulating neutrophil function, regulating cytokine release from epithelial cells, and supporting wound healing through influences on angiogenesis and re-epithelialization. The width of this functional range explains why published LL-37 dosage ranges in research span several orders of magnitude, depending on the experimental endpoint being studied.
LL-37 Dosage Ranges Documented in Published Research
Published LL-37 dosage ranges in the research literature are model-specific and endpoint-specific. In vitro studies have utilized doses across micromolar concentrations to evaluate antimicrobial endpoints, while preclinical models have applied weight-based research doses to study systemic effects in animal subjects. This section organizes the documented ranges into the categories most often referenced when researchers design experimental frameworks.
In Vitro Antimicrobial Dose Research
Across in vitro antimicrobial studies, research subjects (typically bacterial cultures, biofilms, or mammalian cell co-cultures) received LL-37 at concentrations spanning roughly 1 µM to 50 µM, with most minimum inhibitory concentration (MIC) determinations falling between 2 µM and 16 µM depending on the organism. A 2021 study indexed on PubMed Central documented MIC values for LL-37 against multiple gram-negative isolates within this range. Studies utilized doses calibrated to bacterial inoculum size, growth medium ionic composition, and assay duration — three variables that materially shift the apparent antimicrobial potency of the peptide.
Why These Ranges Vary
The apparent LL-37 minimum inhibitory concentration is sensitive to assay conditions. Published research shows that physiological salt concentrations and the presence of serum proteins can reduce LL-37’s antimicrobial activity by binding the cationic peptide and limiting membrane access. As a result, studies utilizing standard Mueller-Hinton broth report different effective concentrations than studies using tissue-mimetic media — and both must be considered when interpreting the published LL-37 antimicrobial dose research.
Preclinical and Animal Model Dose Research
In preclinical models, research subjects received LL-37 at weight-based doses that vary widely by study design and route. Murine studies of wound healing and infection have used local LL-37 application ranging from approximately 5 µg to 500 µg per wound site, while systemic preclinical studies have documented dose ranges expressed in mg/kg. These ranges are reported here strictly as documented in the in vitro and preclinical literature and are not extrapolated to any human-use framework.
Research Insight: Reading Dose Reporting Conventions
When reviewing the LL-37 dosing schedule sections of published papers, look closely at three reported variables:
- The peptide stock solvent and storage buffer (TFA salt vs. acetate salt can shift potency)
- Whether reported concentrations are pre- or post-dilution into the experimental medium
- The peptide purity grade and HPLC verification method used in the source material
Source verification matters. View LL-37 Certificate of Analysis →
How to Source High-Quality LL-37 for Your Research
Quick Answer
Research-grade LL-37 should be sourced from a supplier providing HPLC verification of ≥95% purity, mass spectrometry confirmation of identity, a sterility-tested lyophilized format, and a current Certificate of Analysis. Verify storage recommendations, peptide salt form, and lot-specific purity data before applying any published LL-37 dosage protocol to your experiment.
Source quality is among the largest controllable variables in LL-37 research. The factors below outline what to evaluate before reconstituting a vial and applying any published research dose.
1. HPLC Purity Verification
HPLC purity defines what fraction of a peptide preparation is the intended LL-37 sequence versus truncated, oxidized, or deletion-sequence byproducts. Most published research dose studies assume peptide preparations at ≥95% HPLC purity, with many publications specifying ≥98% for sensitive endpoints. The National Institutes of Health recommends documenting purity certification for all biochemical reagents used in published research.
Researchers should request the chromatogram associated with their lot — not only the summary percentage. A purity figure alone tells you nothing about the impurity profile, and certain sequence-related impurities can independently affect antimicrobial or immunomodulatory readouts.
2. Mass Spectrometry Identity Confirmation
Mass spectrometry confirms that the synthesized peptide matches the theoretical molecular mass of LL-37 (approximately 4,493 Da for the free acid form). Identity confirmation is distinct from purity and addresses a different research validity question — namely, whether you actually have LL-37 in the vial at all.
Reputable suppliers provide MS data alongside HPLC purity certification on the Certificate of Analysis. Studies utilized doses of LL-37 across the published literature universally assume identity-verified peptide.
3. Certificate of Analysis Documentation
A complete Certificate of Analysis (COA) for LL-37 should document peptide sequence, molecular weight, HPLC purity, MS identity confirmation, counter-ion (typically TFA or acetate salt), peptide content (the actual peptide mass per vial after accounting for salt and water), and sterility test results.
Peptide content is frequently overlooked. A vial labeled “5 mg LL-37” may contain only 3.5–4.2 mg of actual peptide once counter-ion mass and bound water are subtracted. Researchers calculating LL-37 mcg per day or per assay should base calculations on peptide content, not gross vial mass.
Ready to source research-grade LL-37? Shop Phoenix Peptide Labs’ verified peptide catalog →
4. Storage and Reconstitution Specifications
LL-37 is typically supplied as a lyophilized powder requiring storage at –20 °C or below. Reconstituted stock solutions degrade more rapidly and are usually aliquoted to minimize freeze-thaw cycles. Storage condition deviations are a leading cause of dose-response variability in published LL-37 research.
A defensible LL-37 cycle length in any experimental protocol should reference the supplier’s documented stability data for both the lyophilized and reconstituted forms.
5. Sterility and Endotoxin Considerations
For research involving mammalian cells or preclinical animal models, endotoxin contamination can independently activate innate immune pathways, confounding any measurement of LL-37 immunomodulatory activity. Low-endotoxin or endotoxin-tested grades are recommended for cell-based and in vivo work.
Suppliers selling exclusively for research use should clearly state their sterility testing protocol. This information should appear on every COA.
6. Supplier Transparency and Lot Traceability
Lot-to-lot variability is a documented source of inconsistency in LL-37 research outcomes. Suppliers should provide unique lot numbers, lot-specific COA documentation, and ideally archive samples for retrospective verification.
For multi-year research programs, document supplier and lot numbers for every published figure — a practice now recommended in FDA guidance on research reagent documentation for studies that may inform future translational research.
LL-37 Research Dose Comparison Across Study Models
The table below summarizes representative LL-37 dosage ranges documented across the most commonly referenced in vitro and preclinical model categories. All values reflect published research conditions; none constitutes administration guidance for human use.
| Study Model | Typical Dose Range | Primary Endpoint | Assay Duration | Reference Notes |
|---|---|---|---|---|
| In vitro MIC (bacterial) | 2–32 µM | Growth inhibition | 18–24 h | Buffer composition critical |
| In vitro biofilm | 10–50 µM | Biofilm disruption | 24–48 h | Higher than planktonic MIC |
| Mammalian cell co-culture | 0.1–10 µM | Immunomodulation | 4–24 h | Cytotoxicity above 25 µM in many cell lines |
| Murine wound model (topical) | 5–500 µg per site | Wound closure rate | 3–14 d | Vehicle formulation variable |
| Preclinical inflammation model | Variable mg/kg | Cytokine modulation | Study-dependent | Wide methodological variability |
| In vitro neutrophil assay | 0.5–5 µM | Chemotaxis / activation | 1–6 h | Low-µM range typical |
Table summary compiled from multiple in vitro and preclinical sources including PMC 2021 and PubMed 2020. Ranges are representative, not exhaustive.
Who Studies LL-37 in Research Settings
LL-37 research spans a range of investigators with different priorities — from purchasing rigor to experimental scaling.
The Lab Purchasing Agent
Coordinates reagent procurement for a multi-PI research program and must balance budget constraints against documented quality requirements for reproducible research.
The Independent Researcher Prioritizing Purity
Runs in vitro assays where small variations in peptide quality directly shift the dose-response curve and require maximum reagent consistency.
The Research Team Scaling an Experiment
Transitioning from pilot data to a larger replication cohort and needs lot consistency, archived samples, and predictable supply across study phases.
Frequently Asked Questions
LL-37 is the only human cathelicidin antimicrobial peptide — a 37-amino-acid cationic peptide cleaved from the precursor protein hCAP18 and active in innate immune defense.
It interacts with anionic bacterial cell membranes to disrupt membrane integrity, and separately modulates immune cells including neutrophils and epithelial cells. A 2021 review on PubMed Central summarizes both the antimicrobial and immunomodulatory mechanisms across published research.
For sourcing questions or documentation requests, contact our team.
Published in vitro studies generally report LL-37 concentrations from approximately 1 µM to 50 µM, with most MIC determinations falling between 2 µM and 16 µM.
Preclinical topical wound studies have used 5 µg to 500 µg per site, and systemic preclinical work reports mg/kg ranges that vary by model. These ranges are documented in peer-reviewed sources on PMC and should never be extrapolated to any human-use protocol.
For sourcing questions or documentation requests, contact our team.
In vitro research consistently documents LL-37 broad-spectrum antimicrobial properties against gram-positive, gram-negative, and certain enveloped viral pathogens.
Activity is concentration-dependent and significantly modulated by assay buffer salt content and serum binding. These findings are summarized in a PubMed-indexed review covering more than a decade of cathelicidin research.
For sourcing questions or documentation requests, contact our team.
Lyophilized LL-37 is typically stored at –20 °C or below, with reconstituted stocks aliquoted to minimize freeze-thaw cycles.
Specific stability windows for both lyophilized and reconstituted forms should be referenced from the supplier’s documented stability data on the Certificate of Analysis. Storage deviations are a leading cause of dose-response variability across published LL-37 dosage research.
For sourcing questions or documentation requests, contact our team.
Need technical specifications or purity documentation? Contact Phoenix Peptide Labs directly →
Research-grade LL-37 carries documented HPLC purity (typically ≥95% or ≥98%), mass spectrometry identity confirmation, sterility testing, and a lot-specific Certificate of Analysis.
Lower grades may have unverified sequence integrity, untested sterility, and no documented impurity profile — making them unsuitable for studies that depend on accurate dose-response characterization. The U.S. National Library of Medicine archives many publications documenting how reagent quality affects research reproducibility.
For sourcing questions or documentation requests, contact our team.
Major limitations include salt and serum sensitivity in vitro, dual concentration-dependent activity (antimicrobial vs. potentially cytotoxic), aggregation in solution, and limited translational data.
Most published findings derive from in vitro and preclinical models, and no controlled clinical evidence supports human therapeutic conclusions. Researchers should interpret all findings within their experimental context.
For sourcing questions or documentation requests, contact our team.
No. LL-37 is not approved by the FDA for human therapeutic, diagnostic, or veterinary use, and is supplied strictly for laboratory research purposes.
All discussion of LL-37 dosage in this guide reflects published in vitro and preclinical research literature only. FDA regulatory information confirms LL-37 is not an approved drug product.
For sourcing questions or documentation requests, contact our team.
In vitro LL-37 studies commonly use micromolar concentrations: 1–16 µM for MIC determinations, 0.1–10 µM for immunomodulatory cell assays, and 10–50 µM for biofilm disruption work.
Specific concentrations depend on the cell type, organism, assay buffer, and endpoint. Reviewing the methods sections of comparable published studies before finalizing protocol concentrations is standard research practice.
For sourcing questions or documentation requests, contact our team.